TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06773468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress management
Description: These different stress management modalities have been developed to ensure equivalent content across: (a) psychoeducation and strategy introduction; and (b) skills-based practice of strategies. Stress management strategies touched on 4 main areas which included (a) pause/break; (b) positive awareness; (c) kindness to self; and (d) social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress management
Description: These different stress management modalities have been developed to ensure equivalent content across: (a) psychoeducation and strategy introduction; and (b) skills-based practice of strategies. Stress management strategies touched on 4 main areas which included (a) pause/break; (b) positive awareness; (c) kindness to self; and (d) social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress management
Description: These different stress management modalities have been developed to ensure equivalent content across: (a) psychoeducation and strategy introduction; and (b) skills-based practice of strategies. Stress management strategies touched on 4 main areas which included (a) pause/break; (b) positive awareness; (c) kindness to self; and (d) social support.
Study: NCT06771700

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative PRAETORIAN Score
Description: The intraoperative PRAETORIAN Score is calculated based on the additional measurements.
Study: NCT04751370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo short-course radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision
Description: Undergo TME
Study: NCT06318273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-969
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-969
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-969
Description: Intravenous (IV) Infusion
Study: NCT05118789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-520
Description: Oral tablet of NVL-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-520
Description: Oral tablet of NVL-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-520
Description: Oral tablet of NVL-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-520
Description: Oral tablet of NVL-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-520
Description: Oral tablet of NVL-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-520
Description: Oral tablet of NVL-520
Study: NCT06526390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: f-URS
Description: f-URS with S-UAS

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mini-PCNL
Description: mini-PCNL
Study: NCT05359822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-Based Report
Description: Participants will receive the new coronary artery calcium score risk report plus the old report
Study: NCT04783857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 200 MG Oral Capsule
Description: Progesterone, 200mg, once daily, oral tablet/capsule
Study: NCT05435066

Intervention type: DIAGNOSTIC_TEST
Intervention: Harbinger Health Test
Description: This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year

Intervention type: DIAGNOSTIC_TEST
Intervention: Harbinger Health Test
Description: This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
Study: NCT05693142

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-202
Description: RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-202
Description: RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
Study: NCT06161571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efruxifermin
Description: Administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efruxifermin
Description: Administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study: NCT06484517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hugemed Videolaryngoscope
Description: After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hugemed Videolaryngoscope
Description: After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.
Study: NCT04855656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: Oral PKMYT1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: Oral PKMYT1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: Oral PKMYT1 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: Oral ATR Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio0123
Description: Oral WEE1 Inhibitor
Study: NCT05723107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
Description: EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes.
Study: NCT05820711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC
Description: Injection of MSCs into submandibular glands at pre-specified dose level:~* Dose -1: 5 (4 - 6) x10\^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~* Dose 0: 10 (8 - 12) x10\^6 MSCs per gland (1 ml)~* Dose 1: 20 (16 - 24) x10\^6 MSCs per gland (2 ml)
Study: NCT05534984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat Oral Capsule
Description: Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat Oral Capsule (Open Label)
Description: * Participants weighing 4 to \<6kg and \>7 days old - Tecovirimat 50mg every 12 hours for 14 days~* Participants weighing 2.5 to \<4kg and \>7 days to \<4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~* Participants weighing 4 to \<6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~* Participants weighing 2.5 to \<4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Study: NCT06233565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
Study: NCT05972837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surface electrical stimulation (SES)
Description: Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation (SES)
Description: Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote medical support
Description: The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
Study: NCT05475015

Intervention type: DEVICE
Intervention: 3D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

Intervention type: DEVICE
Intervention: 3D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

Intervention type: DEVICE
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.

Intervention type: DEVICE
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
Study: NCT05672459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Given by IV (vein)
Study: NCT05322226

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Addiction follow-up before and after liver transplantation
Description: Addiction consult and follow-up
Study: NCT06075121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
Study: NCT06453681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bilateral PECS
Description: ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bilateral PECS
Description: ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
Study: NCT04494451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit C
Description: vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical Treatment
Description: iv antibiotics alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical Treatment
Description: iv antibiotics alone
Study: NCT05594290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab i.v. 500 mg day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/sqm iv. day 1, 2, 3
Study: NCT05311254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin Calcium
Description: Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count \>0,5x109/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Calcium
Description: Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count \>0,5x109/L.
Study: NCT05591053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivSight
Description: Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
Study: NCT04851158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection
Description: Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection
Description: Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants.
Study: NCT05863572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care health worker training
Description: Training primary care workers to detect and treat psychosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care health worker training
Description: Training primary care workers to detect and treat psychosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Workers Training
Description: training community health workers in detection and referral

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Workers Training
Description: training community health workers in detection and referral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits
Description: home visits conducted by people with lived experience of psychosis
Study: NCT06530641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol Htk Soln
Description: Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Custodiol crystalloid cardioplegia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buckberg Cardi-Braun
Description: Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Buckberg blood cardioplegia.
Study: NCT03684564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Oral tablet 15 mg twice daily for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
Study: NCT05003492

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy plus Standard therapy
Description: Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Infected patients will receive the standard therapy for COVID-19 for 14 days
Study: NCT04246164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS combined with CT
Description: HD-tDCS treatments will be administered during a cognitive training session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham HD-tDCS combined with CT
Description: sham-HD-tDCS treatments will be administered during a cognitive training session.
Study: NCT05509049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision nudging
Description: Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care communication (e.g., personalized letters and patient portal notices)
Study: NCT05926440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Description: SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Description: SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Study: NCT05899062

Intervention type: OTHER
Group type: OTHER
Intervention: Education with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp
Description: The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included.

Intervention type: OTHER
Group type: OTHER
Intervention: Training and exercise practices with the telerehabilitation method.
Description: The patients in this group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 6 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.